Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00600964 | A Phase I/II Study of GX15-070MS in Untreated CLL | PHASE1 | COMPLETED | 26 | — | — | Sep 1, 2004 | Jan 1, 2006 | May 12, 2014 | 5 | United States, Canada |
| Arm | Type | Description |
|---|---|---|
| GX15-070MS | EXPERIMENTAL | GX15-070MS at various doses and schedules |
| Name | Type | Description |
|---|---|---|
| GX15-070MS | DRUG | A 60-minute or 3-hour IV infusion every 2-3 weeks. |
Inclusion Criteria: * Histologically or cytologically confirmed B-CLL * Previous standard systemic chemotherapy, including fludarabine. There are no limitations on additional, allowable type and amount of prior therapy. Acute toxicities from prior therapy must have resolved to ≤Grade 1 * Age ≥18 ye...